Effect of Procrit (Epoetin Alfa) on Preventing Delayed Graft Function After Deceased Donor Renal Transplantation

West Penn Allegheny Health System

Status and phase: Completed; Phase 4

Conditions: Delayed Graft Function

Treatments: Drug: Epoetin Alfa

Study type: Interventional

Funder types: Other

Identifiers

NCT00425126

RC-4044

Details and patient eligibility

About

Delayed graft function (DGF) is a major complication following deceased donor renal transplantation. The surgical procedure of harvesting a kidney from a cadaveric donor and implanting the kidney into the recipient inevitably causes some amount of injury. While not always clinically significant, anywhere from 10-50% of transplant patients may develop DGF. Ongoing research in animal models has demonstrated benefit with administration of erythropoietin. The investigators propose to study the effect of Procrit(Epoetin Alfa) on delayed graft function in subjects undergoing kidney transplantation.

Enrollment: 76 patients

Sex: All

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Patients presenting for kidney transplantation
• Age > 18
• Deceased donor kidney transplant

Exclusion criteria

• History of thrombosis or hypercoagulable state
• Receiving Coumadin or Heparin
• Hemoglobin >=14 g/dl
• Uncontrolled hypertension

Trial design

Primary purpose: Treatment

Allocation: Randomized

Interventional model: Single Group Assignment

Masking: Double Blind